[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.127.188. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 498
Citations 0
News From the Food and Drug Administration
November 15, 2016

HCV Drug Warning

JAMA. 2016;316(19):1957. doi:10.1001/jama.2016.16352

The FDA will require boxed warnings on labels for certain direct-acting antiviral medications used to treat hepatitis C virus (HCV) infection following reports that the drugs reactivated hepatitis B virus (HBV) infection.

“Health care professionals should screen all patients for evidence of current or prior HBV infection before starting treatment with [direct-acting antivirals], and monitor patients using blood tests for HBV flare-ups or reactivation during treatment and post-treatment follow-up,” agency officials said in a drug safety communication. “It is currently unknown why the reactivation occurs.”

First Page Preview View Large
First page PDF preview
First page PDF preview
×